First Choice Neurology

First Choice Neurology Research Center 2 Clinical Trials

First Choice Neurology Research Center 2 offer clinical trials in Miami for Alzheimer’s disease, Dementia, and other neurological disorders.

clinical trials in Miami

Acadia – ACP 204 (actively enrolling)
Phase 2/3 study of an oral medication, ACP-204, a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor in adults with Alzheimer’s Psychosis (hallucinations and delusions).

Eli Lilly - TRAILRUNNER-ALZ 3 – LAKF (upcoming study)
Assessment of safety and efficacy of intravenous Remternetug in early symptomatic Alzheimer’s disease.

NEW IDEAS – American College of Radiology/ Alzheimer’s Association – (enrollment closed)
Nationwide Diagnostic study for Medicare patients with memory loss. The study aims to provide an Amyloid PET scan so results can assist the Doctor in the diagnosis and treatment of the patient’s memory condition.

Eli Lilly – Trailblazer 2 – AACI (study active / enrollment closed)
Phase 3 study infusion study to evaluate the safety and efficacy of Donanemab, an antibody in patients with early symptomatic Alzheimer’s Disease. The mechanism of action of the Donanemab antibody is to target and remove deposited amyloid plaque, a key pathological hallmark of AD, via microglial-mediated clearance.

Eli Lilly – Trailblazer 3 – AACM (study active / enrollment closed)
Phase 3 study infusion study to evaluate the efficacy of Donanemab, an antibody that binds to and removes deposited amyloid plaque, in preclinical AD.

Novo Nordisk – Evoke / Evoke+ (study active / enrollment closed)
Phase 3 study investigating the safety and efficacy of oral Semaglutide in participants with Mild Cognitive Impairment (MCI) or mild Dementia of Alzheimer’s type. This treatment is anticipated to delay the decline in cognition and function in these subjects.

Eisai – BAN 2401 (study active / enrollment closed)
Open label - stage study of Lecanemab, a monoclonal antibody (auto-injector) for patients with Mild Cognitive Impairment or Mild Dementia of Alzheimer’s type with confirmed amyloid pathology indicated by positive amyloid load.

SPARC – Proseek (study active / enrollment closed)
Phase 2 study to determine if oral K0706 reduces the rate of progression of early-stage Parkinson’s Disease vs. Placebo


Contact First Choice Neurology Research Center 2

Medical Arts Neurology, LLC
8940 N. Kendall Drive, Suite 802E
Miami, FL 33176
Phone: (305) 595-4041
Fax: (305) 595-6638

Providers:
Victor Faradji, MD
Steven Kobetz, MD
Perla Periut, MD
Carlos Ramirez-Mejia, MD
Jorge Pardo, MD

For more information, please contact:
Eileen Diaz – Ediaz@vintrials.com; 786-744-5597 or
Jonathan Palmquist – Jpalmquist@vintrials.com; 786-744-5596

Translate »
Skip to content